<DOC>
	<DOCNO>NCT01556971</DOCNO>
	<brief_summary>The objective propose study obtain data efficacy Botox reduce symptom MDD male female patient age 18 65 year old . The secondary object visually assess patient 's frown Botox injection determine correlation change frown change mood . The patient photograph screen , visit 2 3 . Their frown line compare determine visible improvement frown line correspond improvement efficacy rating score .</brief_summary>
	<brief_title>Efficacy Study Botox Depression</brief_title>
	<detailed_description>This double-blind study . To maintain blinding study , none investigator assess depression score aware injection status patient . In addition , maintain patient blinding , patient educate possible expect outcomes facial expression . Unless specifically inform , patient generally unaware facial movement inhibit Botulinum Toxin A . An unblinded physician act pharmacist study prepare active drug placebo injection . Duration Treatment : The study divide three phase : screening enrollment , treatment follow-up . Patients meet criterion randomize screen visit . The treatment phase last six ( 6 ) week investigational product administer patient return visit week 3 . Subjects return office discontinuation visit week six . General Design Methodology : At screen , patient sign consent diagnose mean M.I.N.I . They assess clinician perform MADRS CGI-S standardize rating . They complete patient-rated BDI . Subjects provide urine sample drug screening . WOCBP give pregnancy test . Patients meet criterion randomly assign receive either investigational product placebo . The study medication placebo inject procerus corrugator supercilii frown muscle patient physician physician 's assistant . Each patient face photograph visit . Three week ± 7 day follow injection , patient return office clinician administer MADRS CGI-I . The patient complete BDI adverse event ( AEs ) concomitant medication collect . Six week ± 7 day follow injection , patient return office clinician administer MADRS CGI-I , collect AEs concomitant medication . The patient complete BDI . All patient , whether active drug placebo , give voucher may use free Botox injection week 8 , , judgment investigator , beneficial patient . Diagnosis Criteria Inclusion : Patients include study meet follow criterion : - Written inform consent obtain ; - They 18 65 year old ; - They meet DSM-IV criterion MDD diagnose MINI screening , , current episode must least one month length ; - They MADRS score ≥ 26 screening ; - They ≥ 4 CGI-S screen - Women childbearing potential ( WOCBP ) acceptable form birth control pregnant lactating ; - They judge investigator capacity understand nature study ; - They willing comply requirement study . - They consider investigator likely adhere protocol . Criteria Exclusion : Patients exclude study meet follow criterion : - They treat botulinum toxin A 12 month prior screen ; - They another Axis I disorder principal diagnosis 6 month prior screen ; - They history substance abuse dependency 2 month prior screen ( recreational use illicit drug may permissible , discretion investigator ) ; - They test positive illicit drug urine drug screen , adequately explain satisfaction investigator ; - They endorse MADRS item 10 ( suicidal idea ) level 5 attempted suicide six month prior screen ; - They consider significant risk commit homicide ; - They unstable medical condition ; - Women childbearing potential ( WOCBP ) pregnant consider become pregnant length study ; - They regard , reason principal investigator unsuitable candidate protocol . - There change medication psychotherapy treatment regimen month precede screening ; - They prove refractory three adequate antidepressant treatment method different mechanisms action .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>• Written inform consent obtain ; They 18 65 year old ; They meet DSMIV criterion MDD diagnose MINI screening , , current episode must least one month length ; They MADRS score ≥ 26 screening ; They ≥ 4 CGIS screen Women childbearing potential ( WOCBP ) acceptable form birth control pregnant lactating ; They judge investigator capacity understand nature study ; They willing comply requirement study . They consider investigator likely adhere protocol . • They treat botulinum toxin A 12 month prior screen ; They another Axis I disorder principal diagnosis 6 month prior screen ; They history substance abuse dependency 2 month prior screen ( recreational use illicit drug may permissible , discretion investigator ) ; They test positive illicit drug urine drug screen , adequately explain satisfaction investigator ; They endorse MADRS item 10 ( suicidal idea ) level 5 attempted suicide six month prior screen ; They consider significant risk commit homicide ; They unstable medical condition ; Women childbearing potential ( WOCBP ) pregnant consider become pregnant length study ; They regard , reason principal investigator unsuitable candidate protocol . There change medication psychotherapy treatment regimen month precede screen ; They prove refractory three adequate antidepressant treatment method different mechanisms action .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>